DOI: https://doi.org/10.15674/0030-598720103100-104

Our experience of using oral anticoagulant Rivaroxaban in patients after cementless hip joint arthroplasty

Volodymyr Filipenko, Oleg Vyrva, Nataliya Kuznetsova, Roman Malyk, Olga Podgayskaya

Abstract


This article represents the first stage of a research in using a direct oral inhibitor of Xa factor, Rivaroxaban, in patients after cementless hip joint arthroplasty. The purpose of the present research was to study the efficacy and safety of the above drug preparation. The investigation involved 20 patients. The efficacy of this anticoagulant therapy was analysed; its assessment did not reveal either any manifestations of thrombotic complications (thrombosis of deep veins on the lower extremities, pulmonary thromboembolism) or cases of haemorrhagic complications. The safety was assessed by the results of general clinical and biochemical blood tests. This research demonstrated that taking of Rivaroxaban ensured high efficacy of anticoagulant therapy for preventing thromboembolic complications and preserved safety  for patients after hip joint arthroplasty.


Keywords


hip joint; arthroplasty; anticoagulant therapy; Rivaroxaban

References


Вырва О. Е. Сравнение эффективности длительной терапии ривароксабаном и кратковременной эноксапарином для профилактики венозной тромбоэмболии после эндопротезирования тазобедренного сустава. Результаты исследований RECORD 2 [Текст] / О. Е. Вырва // Ортопед. травматол. — 2010. — № 1. — С. 110–114.

Вырва О. Е. Сравнительная оценка эффективности ривароксабана и эноксапарина в профилактике тромбообразования после эндопротезирования тазобедренного сустава. Результаты исследований RECORD 1 [Текст] / О. Е. Вырва // Ортопед. травматол. — 2009. — № 3. — C. 97–100.

Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians — are they appropriate for orthopaedic surgery? [Text] / J. J. Callaghan, L. D. Dorr, G. A. Engh et al. // J. Arthroplasty. — 2005. — Vol. 20. — P. 273–274.

Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD 1 trial [Text] / B. Eriksson, L. Borris, R. Friedman et al. // Blood. — 2007. — Vol. 110. — Аbstract 6.

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty [Text] / B. Eriksson, L. Borris, R. Friedman et al. // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2765–2775.

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) for the American College of Chest Physicians [Text] / W. H. Geerts, D. Bergqvist, G. F. Pine et al. // Chest. — 2008. — Vol. 133. — P. 381–453.

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial [Text] / A. K. Kakkar, B. Brenner, O. E. Dahl et al. // Lancet. — 2008. — Vol. 372. — P. 29–37.

Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study [Text] / P. Prandoni, O. Bruchi, P. Sabbion et al. // Arch Intern Med. — 2002. — Vol. 162. — P. 1966–1971.




Copyright (c) 2014 Volodymyr Filipenko, Oleg Vyrva, Nataliya Kuznetsova, Roman Malyk, Olga Podgayskaya

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.